Want to see ES:FAE full AI Analyst Report?
Top Page
Faes Farma
(BME:FAE)
Select Model
Select Model
Rating:58Neutral
Price Target:
€4.50
▼(-2.17% Downside)
Action:Reiterated
Date:08/04/26
The score is primarily held back by weakening financial performance in 2025 (declining revenue, margin compression, weaker cash conversion, and higher leverage). Technical signals are neutral, offering limited support. Valuation is a relative positive, supported by a moderate P/E and a high dividend yield.
Positive Factors
Vertically integrated business model
Faes Farma’s vertical integration across R&D, manufacturing and commercialization plus exposure to human health, animal health and industrial supply creates durable operational flexibility. Owning manufacturing lowers reliance on third parties, supports gross margins, and enables long-term control of supply and product timing.
Negative Factors
2025 revenue and margin deterioration
A clear step-down in 2025 (declining revenue and sharply compressed margins) signals execution or demand issues that can persist beyond a single quarter. Reduced top-line and margin pressure erodes operating leverage, weakens cash flow and may force reprioritization of R&D or commercial investments, raising medium-term growth risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Vertically integrated business model
Faes Farma’s vertical integration across R&D, manufacturing and commercialization plus exposure to human health, animal health and industrial supply creates durable operational flexibility. Owning manufacturing lowers reliance on third parties, supports gross margins, and enables long-term control of supply and product timing.
Read all positive factors
Faes Farma (FAE) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€1.42B
Dividend Yield4.93%
Average Volume (3M)130.56K
Price to Earnings (P/E)13.7
Beta (1Y)0.45
Revenue Growth31.88%
EPS Growth-20.09%
CountryES
Employees2,679
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.43
Shares Outstanding316,223,940
10 Day Avg. Volume112,243
30 Day Avg. Volume130,562
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)2.16
Price to Sales (P/S)2.63
P/FCF Ratio25.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.32
Revenue Forecast (FY)€758.51M
Faes Farma Business Overview & Revenue Model
Company Description
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of internation...
How the Company Makes Money
Faes Farma makes money mainly by selling pharmaceutical and healthcare products, generating revenue when its medicines and other health products are dispensed or purchased through pharmacies, hospitals, and other healthcare channels. A core compon...
Faes Farma Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
52
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.04B | 610.46M | 493.65M | 451.17M | 438.75M | 398.56M |
| Gross Profit | 312.17M | 228.46M | 326.54M | 297.12M | 282.01M | 252.40M |
| EBITDA | 166.48M | 101.80M | 128.33M | 122.93M | 121.35M | 110.84M |
| Net Income | 136.19M | 79.63M | 111.36M | 91.90M | 89.50M | 82.39M |
Balance Sheet | ||||||
| Total Assets | 1.44B | 1.34B | 853.08M | 776.03M | 725.67M | 641.76M |
| Cash, Cash Equivalents and Short-Term Investments | 136.78M | 130.09M | 72.14M | 47.75M | 84.10M | 73.41M |
| Total Debt | 396.85M | 409.91M | 7.79M | 23.90M | 32.69M | 16.44M |
| Total Liabilities | 664.48M | 594.19M | 126.46M | 112.68M | 123.39M | 103.70M |
| Stockholders Equity | 774.45M | 744.80M | 725.87M | 662.36M | 601.08M | 536.53M |
Cash Flow | ||||||
| Free Cash Flow | 61.63M | 62.38M | 75.95M | -1.22M | 25.84M | 20.23M |
| Operating Cash Flow | 79.45M | 78.49M | 115.47M | 100.97M | 106.79M | 79.64M |
| Investing Cash Flow | -241.15M | -299.02M | -34.18M | -97.36M | -92.17M | -83.48M |
| Financing Cash Flow | 182.02M | 273.62M | -51.71M | -35.38M | -18.46M | -17.12M |
Faes Farma Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €4.88B | 11.90 | 63.53% | 5.59% | 3.79% | -11.33% | |
71 Outperform | €153.47M | 15.20 | 46.32% | 11.36% | -3.63% | 2.37% | |
62 Neutral | €2.42B | 33.50 | 4.78% | 1.63% | 12.41% | 342.01% | |
60 Neutral | €5.93B | 14.87 | 8.43% | 0.85% | -0.33% | 51.93% | |
58 Neutral | €1.42B | 13.74 | 18.19% | 4.89% | 31.88% | -20.09% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €219.01M | 49.26 | 2.01% | 0.74% | -3.23% | -60.06% |
* General Sector Average
ES:FAE
Faes Farma
4.52
0.39
9.50%
ES:ALM
Almirall
10.84
0.68
6.64%
ES:GRF
Grifols
10.18
-2.56
-20.12%
ES:RJF
LABORATORIO REIG JOFRE
2.71
-0.21
-7.10%
ES:LOG
Compania de Distribucion Integral Logista Holdings
36.70
9.32
34.04%
ES:NTH
Naturhouse Health
2.55
0.86
50.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.